Pyxis Oncology’s (PYXS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research note published on Friday morning,Benzinga reports. They currently have a $5.00 price target on the stock, down from their previous price target of $7.00.

A number of other equities analysts also recently weighed in on the stock. William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. Stephens started coverage on shares of Pyxis Oncology in a report on Friday, November 8th. They issued an “overweight” rating and a $13.00 price target for the company. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $8.00 price objective (down previously from $10.00) on shares of Pyxis Oncology in a report on Friday. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.43.

Pyxis Oncology Stock Performance

Shares of NASDAQ:PYXS opened at $1.69 on Friday. The business has a fifty day moving average of $2.93 and a 200-day moving average of $3.29. Pyxis Oncology has a twelve month low of $1.49 and a twelve month high of $6.85. The firm has a market cap of $100.50 million, a PE ratio of -1.64 and a beta of 1.00.

Insider Buying and Selling at Pyxis Oncology

In related news, CFO Pamela Ann Connealy acquired 88,850 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was acquired at an average price of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the acquisition, the chief financial officer now owns 1,199,143 shares of the company’s stock, valued at $2,350,320.28. This trade represents a 8.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 9.80% of the company’s stock.

Hedge Funds Weigh In On Pyxis Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fullcircle Wealth LLC acquired a new stake in shares of Pyxis Oncology in the 2nd quarter valued at approximately $40,000. Intech Investment Management LLC bought a new stake in Pyxis Oncology in the third quarter valued at approximately $55,000. SG Americas Securities LLC acquired a new stake in Pyxis Oncology in the third quarter worth $58,000. The Manufacturers Life Insurance Company bought a new position in shares of Pyxis Oncology during the second quarter worth $65,000. Finally, MetLife Investment Management LLC boosted its position in shares of Pyxis Oncology by 41.1% during the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares in the last quarter. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.